| 32.77 0.3 (0.92%) | 01-14 11:20 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.03 | 1-year : | 45.59 |
| Resists | First : | 33.41 | Second : | 39.03 |
| Pivot price | 31.85  |
|||
| Supports | First : | 30.39 |
Second : | 28.52 |
| MAs | MA(5) : | 32.42 |
MA(20) : | 31.49 |
| MA(100) : | 23.74 |
MA(250) : | 19.48 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 71.2 |
D(3) : | 74.8 |
| RSI | RSI(14): 68.8 |
|||
| 52-week | High : | 33.41 | Low : | 12.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TEVA ] has closed below upper band by 27.9%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.86 - 33.03 | 33.03 - 33.17 |
| Low: | 31.6 - 31.77 | 31.77 - 31.92 |
| Close: | 32.21 - 32.49 | 32.49 - 32.71 |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Wed, 14 Jan 2026
Teva Is No Longer A Turnaround Story—It's A Growth One (NYSE:TEVA) - Seeking Alpha
Mon, 12 Jan 2026
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Zacks Investment Research
Mon, 12 Jan 2026
Why Is TEVA Stock Rising Pre-Market Today? - Stocktwits
Mon, 12 Jan 2026
Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance - MarketBeat
Mon, 12 Jan 2026
Teva lines up $500M in Royalty Pharma funding for vitiligo drug - Fierce Biotech
Mon, 12 Jan 2026
Teva inks deal with Royalty Pharma on potential vitiligo drug - The Pharma Letter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,150 (M) |
| Shares Float | 1,140 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 58.9 (%) |
| Shares Short | 44,940 (K) |
| Shares Short P.Month | 46,440 (K) |
| EPS | 0.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.32 |
| Profit Margin | 4.2 % |
| Operating Margin | 23.7 % |
| Return on Assets (ttm) | 5.4 % |
| Return on Equity (ttm) | 9.7 % |
| Qtrly Rev. Growth | 3.4 % |
| Gross Profit (p.s.) | 7.3 |
| Sales Per Share | 14.59 |
| EBITDA (p.s.) | 3.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,070 (M) |
| Levered Free Cash Flow | 1,020 (M) |
| PE Ratio | 53.04 |
| PEG Ratio | 0 |
| Price to Book value | 5.11 |
| Price to Sales | 2.21 |
| Price to Cash Flow | 34.77 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|